Journal of Cancer Therapy

Vol.4 No.2(2013), Paper ID 29922, 4 pages

DOI:10.4236/jct.2013.42075

 

Complete Remission and Long Term Survival in Recurrent Malignant Glioblastoma Treated with Fotemustine Monotherapy: A Case Report

 

Carmine Cerullo, Carla Fonte, Andrea Muto, Agnese Vannini, Mattia Rediti, Sheila Rangan, Lorenzo Bordi, Bruno Neri

 

Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy
Interventional Neuroradiology, Florence, Italy.
Department of Oncology—Center of Experimental and Clinical Oncology, University of Florence, Florence, Italy

 

Copyright © 2013 Carmine Cerullo, Carla Fonte, Andrea Muto, Agnese Vannini, Mattia Rediti, Sheila Rangan, Lorenzo Bordi, Bruno Neri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


C. Cerullo, C. Fonte, A. Muto, A. Vannini, M. Rediti, S. Rangan, L. Bordi and B. Neri, "Complete Remission and Long Term Survival in Recurrent Malignant Glioblastoma Treated with Fotemustine Monotherapy: A Case Report," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 584-587. doi: 10.4236/jct.2013.42075.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.